10-Q: Intuitive Surgical Reports Strong Q3 2026 Growth

Intuitive Surgical announced a 22% revenue increase to $3.05 billion in Q3 2026, driven by a 14% rise in da Vinci procedures and a 31% surge in Ion procedures.

Summary

• Intuitive Surgical reported a 22% year-over-year increase in total revenue for the third quarter of 2026, reaching $3.05 billion.
• Da Vinci procedures grew by 14% to approximately 906,000, while Ion procedures saw a significant 31% increase to approximately 49,700.
• Systems revenue grew by 30% to $769 million, supported by a 28% increase in da Vinci system placements.
• The company recorded a $450 million charge related to the settlement of an antitrust class action litigation.
• Cash, cash equivalents, and investments decreased to $6.80 billion, primarily due to stock repurchases and a business acquisition.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with robust revenue growth, increased procedure volumes, and strategic acquisitions bolstering future prospects, despite ongoing litigation costs.

Positives

• Total revenue increased by 22% to $3.05 billion in Q3 2026 compared to $2.51 billion in Q3 2025.
• Da Vinci procedures increased by 14% to approximately 906,000 in Q3 2026.
• Ion procedures increased by 31% to approximately 49,700 in Q3 2026.
• Instruments and accessories revenue grew by 18% to $1.80 billion.
• Systems revenue increased by 30% to $769 million.
• Da Vinci surgical system placements increased by 28% to 546 units.
• Gross profit as a percentage of revenue improved to 68.4% from 66.4% in the prior year period.
• The company acquired ab medica, Abex, Excelencia Robtica, and their affiliates for approximately $533.1 million, strengthening its direct distribution in key European markets.

Negatives

• Operating income decreased by 22% to $592.6 million in Q3 2026 compared to $759.7 million in Q3 2025, largely due to a $450 million settlement charge for antitrust class action litigation.
• Cash, cash equivalents, and investments decreased by $2.23 billion to $6.80 billion as of September 30, 2026, from $9.03 billion as of December 31, 2025, primarily due to significant stock repurchases and an acquisition.
• The company expects to implement price reductions on instruments sold in China, potentially reducing instruments and accessories revenue per procedure by 3% to 5%.

Risks

• Third parties may offer remanufactured instruments and accessories or unauthorized service, potentially impacting financial results, patient safety, and reputation.
• The company faces competition from domestic and international manufacturers of robotic-assisted surgical systems.
• Changes in tariffs, trade barriers, and regulatory requirements could materially impact the business.
• Macroeconomic and geopolitical factors, including inflation, interest rates, and supply chain disruptions, could adversely affect future results.
• Elongated regulatory approval timelines may extend the introduction of new products and indications.
• The proposed settlement of the antitrust class action litigation is subject to court approval and potential objections from class members.

Future Outlook

The company expects to continue making substantial investments in research and development, anticipating further increases in R&D expenses. Pricing actions in China and for certain instruments are expected to reduce instruments and accessories revenue per procedure by approximately 3% to 5% once fully implemented. Future system placements will be impacted by various factors including supply chain risks, economic conditions, competition, and regulatory approvals.

Management Comments

• The company believes that minimally invasive care is life-enhancing care and is committed to advancing it through its ecosystem of products and services.
• The company aims to achieve the Quintuple Aim: better patient outcomes, better patient experiences, better experiences for healthcare teams, lower total cost of care, and expanded access to care.
• Management believes procedure volume is an indicator of adoption and future revenue, providing meaningful supplemental information regarding performance.
• The company continues to monitor macroeconomic and geopolitical factors, including tariffs, inflation, interest rates, and supply chain disruptions, which could materially affect future results.

Industry Context

StockSavvy.ai notes that Intuitive Surgical continues to dominate the robotic-assisted surgery market, with strong growth in both its established da Vinci system and its emerging Ion endoluminal system. The company's strategic acquisition and expansion into direct distribution in key European markets highlight its commitment to global market penetration. However, increasing competition and regulatory scrutiny, particularly in China, present ongoing challenges.

Comparison to Industry Standards

• Intuitive Surgical's revenue growth of 22% in Q3 2026 outpaces the general medical device industry's growth rates, which have been impacted by supply chain issues and economic uncertainty.
• The company's da Vinci procedure growth of 14% demonstrates continued adoption of robotic-assisted surgery, a trend that is expected to continue across the surgical robotics sector.
• The 31% growth in Ion procedures indicates successful market penetration for its endoluminal system, a segment that is relatively nascent but holds significant potential for diagnostic procedures.
• The company's gross profit margin of 68.4% is robust and generally higher than many other medical device manufacturers, reflecting its strong market position and recurring revenue streams from instruments and services.

Legal Proceedings

• Product liability lawsuits alleging injuries and deaths resulting from the use of the da Vinci surgical system.
• Antitrust class action litigation related to the service and repair of certain instruments, with a settlement agreement reached for $450 million.
• Antitrust litigation filed by Restore Robotics Repairs regarding service and replacement of EndoWrist instruments, currently in appeal.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth and procedure volume, partially offset by litigation settlement costs and significant share repurchases.
• Customers (Hospitals/Healthcare Systems): Continued access to advanced robotic surgical technology, with potential cost reductions in instruments per procedure in the future.
• Suppliers: Potential for increased demand due to higher system placements and procedure volumes, but also subject to supply chain risks and tariff impacts.
• Employees: Continued investment in R&D and commercial operations suggests ongoing employment opportunities; share-based compensation remains a significant expense.

Next Steps

• Finalize the allocation of purchase consideration for the ab medica acquisition.
• Continue to seek regulatory clearances and approvals for new indications and markets for da Vinci and Ion systems.
• Implement planned instrument pricing actions in China and for certain core instruments.
• Monitor and manage supply chain risks and macroeconomic factors impacting operations and customer spending.
• Proceed with the settlement of the antitrust class action litigation, subject to court approval.

Key Dates

Recommendation

While Intuitive Surgical demonstrates strong operational performance with significant revenue and procedure growth, the substantial $450 million litigation settlement, ongoing legal risks, and expected price reductions in China warrant a cautious approach. The company's market leadership and innovation are clear positives, but these factors necessitate a 'hold' rating until the impact of these headwinds is more fully understood and resolved.

Keywords

robotic surgery, surgical systems, medical devices, minimally invasive surgery, da Vinci system, Ion endoluminal system, healthcare technology, procedure volume